Roche Holding AG
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 57
- Registration Number
- NCT00048126
A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002377
- Locations
- πΊπΈ
Univ of California / San Diego / Dept of Pediatrics, La Jolla, California, United States
πΊπΈSt Luke's - Roosevelt Hosp Ctr / Div of Infect Dis, New York, New York, United States
πΊπΈNew York Hosp - Cornell Med Ctr, New York, New York, United States
A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 528
- Registration Number
- NCT00002117
- Locations
- πΊπΈ
Intergrated Care Ctr, Atlanta, Georgia, United States
πΊπΈVeterans Administration Med Ctr, Washington, District of Columbia, United States
πΊπΈWashington Univ, St. Louis, Missouri, United States
Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00002256
- Locations
- πΊπΈ
Hoffmann - La Roche Inc, Nutley, New Jersey, United States
A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT00002034
- Locations
- πΊπΈ
Dr Alfred F Burnside Jr, Columbia, South Carolina, United States
πΊπΈSUNY / Health Sciences Ctr at Stony Brook, Stony Brook, New York, United States
π¨π¦Southern Alberta HIV Clinic / Foothills Hosp, Calgary, Alberta, Canada
A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 225
- Registration Number
- NCT00002247
- Locations
- πΊπΈ
Mount Zion Med Ctr, San Francisco, California, United States
πΊπΈDr Dorothy Friedberg, New York, New York, United States
πΊπΈGeorgetown Univ Med Ctr, Washington, District of Columbia, United States
Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection
- Conditions
- Cytomegalovirus RetinitisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 500
- Registration Number
- NCT00017784
- Locations
- πΊπΈ
Retina - Vitreous Associates Med Group, Beverly Hills, California, United States
πΊπΈSanta Clara Valley Med Ctr, San Jose, California, United States
πΊπΈQuest Clinical Research, San Francisco, California, United States
Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 300
- Registration Number
- NCT00001040
- Locations
- πΊπΈ
Stanford Univ Med Ctr, Stanford, California, United States
πΊπΈUniv of Colorado Health Sciences Ctr, Denver, Colorado, United States
πΊπΈBellevue Hosp / New York Univ Med Ctr, New York, New York, United States
A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir
- Conditions
- HIV InfectionsCytomegalovirus Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT00002251
- Locations
- πΊπΈ
Davies Med Ctr, San Francisco, California, United States
πΊπΈGeorgetown Univ Med Ctr, Washington, District of Columbia, United States
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT00002162
- Locations
- πΊπΈ
UCD Med Ctr, Sacramento, California, United States
πΊπΈRush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
πΊπΈUCSD Treatment Ctr, San Diego, California, United States